SYBX (Synlogic Inc.) יחס שווי שוק לשווי בספרים

Synlogic, Inc. (SYBX) leverages bioengineering developments for the therapy of metabolic disorders, generating profit through alliances with major corporations. However, competitive advantages have currently been eroded due to the freezing of core projects, and capital has stalled at 0.63. This daily price chart complements data regarding the staff of experts creating innovative "living" drugs to combat genetic malfunctions of the body.

This metric is calculated as the ratio of the current market value of all shares to the company's net equity. The metric determines the premium the market is willing to pay for assets above their book value. For Synlogic, Inc. (SYBX), the transition to intellectual property licensing reduces capital expenditures, shifting value into intangible assets. Analyzing the change in the company's P/BV ratio allows for an assessment of the effectiveness of this digital transformation. Low values here may signal either an undervaluation or a risk of asset impairment.